RE:Here we go again with the same pump.Investor fatigue is common, especially with biotech. Drugs can take forever to get approved, longer to monetize, and longer yet to become profitable. The AQS chart has performed about as expected with the sp eroding from its initial days of euphoria, through the biotech bubble pop, and into the dog days before profitability. That being said, revenue is growing, costs are falling, and adequate financing is in place to see the company to its next milestones. I have been watching AQS for sometime, but only finally took a piece (@ 28 cents) after 3 quarters of actual revenue were in the books *and* a new round of financing in place. I can't speak for the last 2 years, but as of today there is a recipe for share growth, most of which is covered by the pumpers, but with Canada having dense population pockets, AQS can access those markets with a very small sales force - costs *should* be able to be kept under control. The elements are there. Anxious to see Q4 numbers.